Screener
Aquestive Therapeutics, Inc. AQST License and royalty revenue (a) — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Manufacture and supply revenue | $11,911 | $9,583 | $20,704 | $16,776 |
| License and royalty revenue (a) | 1,326 | 839 | 6,721 | 1,629 |
| Co-development and research fees | 582 | 378 | 840 | 796 |
| Proprietary product revenue, net | — | (797) | — | (478) |
| Total revenues | $13,819 | $10,003 | $28,265 | $18,723 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s license and royalty revenue (a) — revenue?
- Aquestive Therapeutics, Inc. (AQST) reported license and royalty revenue (a) — revenue of $1.33M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s license and royalty revenue (a) — revenue changed year-over-year?
- Aquestive Therapeutics, Inc.'s license and royalty revenue (a) — revenue increased by 58.0% year-over-year, from $839K to $1.33M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s license and royalty revenue (a) — revenue?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s license and royalty revenue (a) — revenue has grown at a -14.9% compound annual growth rate (CAGR), from $6.71M to $3.52M.
- What does license and royalty revenue (a) — revenue mean?
- This metric represents the total revenue recognized from licensing intellectual property and royalty payments received from third-party partners for the commercialization of the company's proprietary pharmaceutical technologies. It reflects the monetization of the company's R&D efforts through external partnerships rather than direct product sales. This stream is a key indicator of the company's ability to generate recurring, high-margin cash flow from its technology platform and patent portfolio.
Ask your AI about Aquestive Therapeutics, Inc.'s license and royalty revenue (a) — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude